Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease

Plain-language summary

This study examines biomarkers of the BDNF pathway in the cerebrospinal fluid of people with Huntington's disease, using brain MRI, lumbar puncture, blood samples and cognitive assessment. It can enroll patients aged 18 and older with genetically confirmed Huntington's disease (35 or more CAG repeats in the HTT gene) along with age-matched control participants. It is a study without an assigned phase and is still recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

University Hospital, Montpellier

Intervention

Brain MRI, Lumbar Punction, Blood sample, Cognitive evaluation

Start date

3/3/2020

Estimated completion

9/1/2027

Countries

France

Related genes

Locations

• Montpellier, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* General inclusion criteria:

  * age ≥ 18 years-old
  * national health insurance cover
* Patients inclusion criteria:

  * genetically confirmed Huntington's disease diagnosis (≥ 35 CAG repeat in HTT gene exon 1)
  * written informed consent
  * only for patients "with lumbar puncture (LP)": patient agreement for LP
* Control inclusion criteria:

  * anterior LP for medical reason with consent for biobank "Neuro" with following samples present in this biobank : 2 mL blood + 0.5 mL plasma + 0.5 mL cerebrospinal fluid
  * information and non-opposition for the finality of this biobank
  * paired by age with a patient (+/- 5 years difference)

Exclusion Criteria:

* General exclusion criteria:

  * protected by law
* Patients exclusion criteria:

  * Huntington's disease stage too Evolved that may interfere with cognitive evaluations or MRI
  * contraindications to brain MRI
  * only for patients "with LP": contraindications to LP
  * incapacity to give informed consent
* Control exclusion criteria:

  * neurodegenerative of inflammatory central nervous system pathology